Kaempferia parviflora Ethanol Extract, a Peroxisome Proliferator-Activated Receptor Ligand-binding Agonist, Improves Glucose Tolerance and Suppresses Fat Accumulation in Diabetic NSY Mice

被引:20
|
作者
Ochiai, Masaru [1 ]
Takeuchi, Toshiki [2 ]
Nozaki, Tsutomu [3 ]
Ishihara, Ken-o [3 ]
Matsuo, Tatsuhiro [2 ]
机构
[1] Kitasato Univ, Sch Vet Med, 23-35-1 Higashi, Towada, Aomori 0348628, Japan
[2] Kagawa Univ, Fac Agr, Kita Ku, 2393 Ikenobe, Miki, Kagawa 7610795, Japan
[3] BHN Co Ltd, Chiyoda Ku, 1-16 Kandanishiki, Tokyo 1010054, Japan
关键词
fat accumulation; glucose tolerance; Kaempferia parviflora; methoxy flavone; PPAR; ETHYL-ACETATE EXTRACT; TISSUE DISTRIBUTION; INSULIN-RESISTANCE; PANCREATIC LIPASE; PPAR-GAMMA; 5,7-DIMETHOXYFLAVONE; MOUSE; RAT; POLYMETHOXYFLAVONOIDS; PHARMACOKINETICS;
D O I
10.1111/1750-3841.14437
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
This study assessed the effect of Kaempferia parviflora, also known as black ginger (BG), and its ethanol extract (BGE) on peroxisome proliferator-activated receptor (PPAR) agonistic activity, glucose tolerance, fat accumulation, and lipids-induced hypertriglyceridemia in mice. PPAR ligand-binding capacity in vitro and polymethoxy flavone contents were highly observed in organic solvent extracts. In an animal experiment A, male diabetic Nagoya-Shibata-Yasuda mice were divided into five dietary groups and fed each diet for 8 weeks: AIN-93G diet (low-fat [LF] diet), high-fat (HF) diet, HF diet supplemented with 1% BG, HF diet supplemented with 0.19% BGE, and HF diet supplemented with pioglitazone (PPAR agonist, 3 mg/kg/day) as a PPAR agonistic positive control. As determined from glucose and insulin tolerance tests, plasma glucose levels were improved in the BG and BGE groups. The BGE extract suppressed fat accumulation in adipose tissues, liver, and muscles without changing the plasma adiponectin level. In an animal experiment B, in order to investigate the effect of BG and BGE on lipid-induced hypertriglyceridemia, male ddY mice were divided into three test groups: control, BG-administered group (500 mg/kg), and BGE-administered group (100 mg/kg). The plasma triacylglycerol level was not different among the groups during the lipids administration test. These results conclude that the BGE extract containing several kinds of polymethoxy flavones showed PPAR ligand-binding capacity in vitro and prevented obesity and insulin resistance independent of adiponectin secretion in mice.
引用
收藏
页码:339 / 348
页数:10
相关论文
共 50 条
  • [31] Crystal structures of the ligand-binding domain of human peroxisome proliferator-activated receptor δ in complexes with phenylpropanoic acid derivatives and a pyridine carboxylic acid derivative
    Oyama, Takuji
    Takiguchi, Kazuki
    Miyachi, Hiroyuki
    ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS, 2022, 78 : 81 - 87
  • [32] The Peroxisome Proliferator-Activated Receptor (PPAR) α Agonist Fenofibrate Suppresses Chemically Induced Lung Alveolar Proliferative Lesions in Male Obese Hyperlipidemic Mice
    Kuno, Toshiya
    Hata, Kazuya
    Takamatsu, Manabu
    Hara, Akira
    Hirose, Yoshinobu
    Takahashi, Satoru
    Imaida, Katsumi
    Tanaka, Takuji
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (05): : 9160 - 9172
  • [33] Effects of tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist on atherosclerosis and visceral fat in low density lipoprotein receptor deficient mice
    Chira, Ebele C.
    McMillen, Timothy
    Wang, Shari
    Chait, Alan
    DIABETES, 2006, 55 : A153 - A153
  • [34] Peroxisome proliferator-activated receptor-α agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis
    Kim, H
    Haluzik, M
    Asghar, Z
    Yau, D
    Joseph, JW
    Fernandez, AM
    Reitman, ML
    Yakar, S
    Stannard, B
    Heron-Milhavet, L
    Wheeler, MB
    LeRoith, D
    DIABETES, 2003, 52 (07) : 1770 - 1778
  • [35] The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects
    Hanf, Remy
    Millatt, Lesley J.
    Cariou, Bertrand
    Noel, Benoit
    Rigou, Geraldine
    Delataille, Philippe
    Daix, Valerie
    Hum, Dean W.
    Staels, Bart
    DIABETES & VASCULAR DISEASE RESEARCH, 2014, 11 (06): : 440 - 447
  • [36] Peroxisome proliferator-activated receptor (PPAR)-α activation increases fatty acid oxidation and improves hyperglycemia in a model of type 2 diabetic mice
    Kim, H
    Fernadez, AM
    Reitman, ML
    Yakar, S
    Leroith, D
    DIABETES, 2002, 51 : A327 - A327
  • [37] Peroxisome proliferator-activated receptor α ( PPARα) agonist treatment reverses PPARα dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice
    Fischer, M
    You, M
    Matsumoto, M
    Crabb, DW
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (30) : 27997 - 28004
  • [38] CENTIPEDEGRASS STIMULATES GLUCOSE UPTAKE THROUGH REGULATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA IN 3T3-L1 ADIPOCYTE AND IMPROVES GLUCOSE TOLERANCE IN MICE FED HIGH-FAT DIET
    Park, C. -H.
    Bai, H. -W.
    Kim, D. -H.
    Cho, J. Y.
    Chung, B. Y.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S165 - S165
  • [39] Peroxisome proliferator-activated receptor-α selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice
    Srivastava, Rai Ajit K.
    Jahagirdar, Ravi
    Azhar, Salman
    Sharma, Somesh
    Bisgaier, Charles L.
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2006, 285 (1-2) : 35 - 50
  • [40] Peroxisome proliferator-activated receptor-α selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice
    Rai Ajit K. Srivastava
    Ravi Jahagirdar
    Salman Azhar
    Somesh Sharma
    Charles L. Bisgaier
    Molecular and Cellular Biochemistry, 2006, 285 : 35 - 50